Shenzhen Builds Up R&D Platform For New Combination Drugs
This article was originally published in PharmAsia News
Shenzhen National Biomedical Industry Base recently released its key R&D results at China Hi-Tech Fair. Last March, Shenzhen Ausa Pharmed Co., which has been appointed the new combination drug research center for the biomedical base, received Class I new drug certification from China's State FDA for its enalapril maleate and folic acid tablet. This represents the only new drug with intellectual property rights to obtain such certification in the cardiovascular field in the past three years. Experts observe that innovative drug combination, complemented with expansion of drug indications, may form an effective approach that suits China's situation and helps the nation catch up in the global innovation competition. (Click here for more - Chinese Language)
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.